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The Receptor Competition Model
An important issue for any modeling of clinical situations is the target engagement of the antipsychotics at their respective clinical dose. To calculate the functional free concentration of the drug, we use the receptor competition model, a set of ordinary differential equations that describe the competition between neurotransmitter, drug, its metabolite and a possible radiotracer [1] .
Basically the receptor competition model is a set of ordinary differential equations that describes the time-dependent changes in pre-and postsynaptic receptor activations, neurotransmitter and drug levels in the synaptic cleft and amount of binding to different receptors. We use a series of differential equations that simulate the binding of up to four agents at pre-and postsynaptic receptors based upon their respective affinities under realistic presynaptic firing conditions of the endogenous neurotransmitter [1] .
Where n is for neurotransmitter. Similar equations are used for drug1, drug2 and tracer. R f denotes the level of free receptor; k on is the on-rate (usually diffusional controlled if not experimentally determined) and K d is the dissociation constant.
Exponential decay of the neurotransmitter is defined as [NT](t) = [NT(0)]*exp(-t ln(2)/halflife) (Eq S2)
where halflife is the half-life of the decay process. This is modulated by transporters (in the case of DA, 5-HT and NE) or enzymes (Acetylcholinesterase for Ach and Catechol-OMethyl transferase for DA and NE).
The amount of presynaptic receptor activation which occurred 150 ms before the current release event then determines the amount of new release as follows where release 0 is the base release amount, relScale is the maximum relative change for release, recAct is the receptor activation at the specified time in the past, relSens is the sensitivity to presynaptic receptor (lower values create a shallow response and higher values create a sharp difference between activation levels), and normBound is the amount of normal presynaptic binding that one would expect in the tonic case (i.e. when recAct equals normBound, the new relase equals the baseline release amount). We calibrate the parameters so that the coupling of presynaptic D2R activation to dopamine release reflects actual experimental data (as seen in Results section). All differential equations are solved with a fourth-order Runge-Kutta method with a time step of 0.01 msec.
In addition, the release can be modulated by a depression or facilitation mechanism [2] .
Instead of using internal Ca ++ levels to determine dopamine release, we consider the facilitation and depression of dopamine release based solely on the amount of time elapsed since the previous firing using a phenomenological equation. Thus, the amount of dopamine released is based both on the history of firing and the activation level of the presynaptic D2 autoreceptors. If we denote the time of the n th firing by t n , then the release amount is modified based on all previous firings as follows
where w f is the facilitation weight, w d is the depression weight, k f is the decay rate of facilitation and k d is the decay rate of depression. All these parameters can be calibrated to experimental data if they are available.
The simulation is initiated by first finding the equilibrium given a constant amount of free dopamine at 500 nM. The simulation is then run for a transitory time of 5 seconds at the tonic firing rate of 4 Hz.
All the parameters that describe the presynaptic neurotransmitter physiology are calibrated with preclinical experiments using rapid-cyclic fast voltammetry on levels of neurotransmitters [3, 4] .
We use this model in two steps. First, the functional free intrasynaptic concentration of the drugs is determined by simulating the competition between total active moiety (including the active metabolite) and tracer at the postsynaptic D 2 R in a PET radiotracer displacement study [5] . For cortical drug concentrations we use tracer displacement data of various antipsychotics on FLB417 [6] . Using the competition model between neurotransmitter, drug and tracer for binding at the postsynaptic receptor, we can determine the drug concentration that corresponds to a clinically measured radiotracer displacement. This value for the drug concentration is the free and functional intra-synaptic concentration that is dependent upon the PK properties of the drug and is used in further calculations. For all the studies we assume steady-state plasma and target engagement values.
Second, we can then use this free functional concentration of the active moiety to calculate the postsynaptic receptor activation in other non-dopaminergic D 2 synapses, dependent upon the affinity of the drug, its metabolite and the endogenous neurotransmitter (such as 5-HT or Ach). The change in the appropriate postsynaptic receptor activation is then used to derive the change in voltage-mediated ion channels that drive the excitability of the network (see below).
Calibration of the serotonergic synaptic cleft model
The serotonergic synaptic cleft model is calibrated using both in vivo experimental data on free 5-HT levels in preclinical animal models and human imaging data using specific radiotracers. The preclinical data measure the free serotonin levels during forced firing frequency of the presynaptic terminals and therefore probe the effect of presynaptic 5-HT1B autoreceptor coupling and The following table then shows the values of the adjustable parameters of the serotonergic synapse (for a definition of the parameters, see Methods Section) for each of the cases that refer to the ratio between intrasynaptic and extrasynaptic 5-HT levels.
The calibration is performed using mouse data; however we are interested in the human situation. Unfortunately we don't have access to free 5-HT levels in human brain. The closest we can get is the result of PET radiotracer displacement imaging studies using 5-HTR specific radio-tracers.
The strategy is to select the parameter set in Table 2 within the 1x-10x range that best fits the displacement of 5-HT2AR tracers in schizophrenia patients treated with certain antipsychotics with affinity for the 5-HT2AR.
The following table lists the different published imaging studies in schizophrenia and the effect of antipsychotics on displacement of specific 5-HTR radiotracers. In some publications also the corresponding D2R occupancy is given; in all the other cases we use values of raclopride D2R displacement obtained from independent imaging trials using the same clinical doses. The imaging studies with WAY100635 after aripiprazole in schizophrenia patients suggest a low receptor occupancy of about 16% despite a high affinity of aripiprazole for this receptor (3-4 nM),
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where it is documented to be a partial agonist [16] . As the authors acknowledge in their discussion, this is likely due to the fact that the binding affinity in vitro is measured using a labeled agonist (8- [17, 18] . For this reason we eliminated this 5-HT1A imaging study leaving us with seven studies on the 5-HT2AR.
Binding studies using radio-active tracers usually probe the low-energy desensitized state [17] .
In this study however we need to use the association kinetics for the active state, as the experimental conditions studies the effect of released serotonin on the presynaptic physiology following activation of the 5-HT1B autoreceptor. Also, in all other simulations, we study the effect of interventions on the active state of pre-and postsynaptic receptors.
We use the following values for the different 5-HTR. We can calculate functional brain concentration of the antipsychotic drugs using published data on raclopride D2R displacement. For each of the conditions mentioned above, we can then simulate the displacement of the tracers setoperone or altanserin by the appropriate functional brain concentration of the antipsychotic, given its known affinity for the human 5-HT2AR. Because the amount of tracer displacement results from a complex interaction between tracer, drug and serotonin, it will depend upon the level of free 5-HT. A proper alignment with the clinical imaging data will gives us a better idea of the actual 5-HT levels that are driving the 5-HT dynamics at least in schizophrenia patients. We further assume that these values can be extrapolated to normal healthy subjects, as schizophrenia is mostly associated with a dopamine dysfunction [24] .
Affinity of 5-HT for
The following Where A m and Cer m are the specific radio-active signal in the region of interest (i.e. striatum and cerebellum, respectively).
We used radio-tracers at a concentration of 10 pM and the corresponding values for K d from 
Table.6 Affinity of drugs (k i ) measured using competition with labeled antagonists. The last column shows the obtained free functional concentrations for the compound that match the reported clinical raclopride striatal D2R displacements. All compounds are antagonists except where noted as pa X (Y%) where X is the EC 50 of the compound in nM and Y is the E max of functional activation (usually expressed as a percentage of the full agonist activation level).
Because raclopride displacement is measured functionally it takes into account many confounding issues such as blood-brain barrier transport and free fraction etc. and reflects the actual true concentration of the drug. 
The Cortical Network
We extended a biophysically realistic model of a network comprised of 20 fourcompartment pyramidal cells and 10 two-compartment GABA interneurons [32, 33] with the receptor physiology of 18 different dopaminergic, serotonergic, noradrenergic, and cholinergic receptors (Fig 1) . We only discuss here the changes relative to the published paper. Basically this network is a smaller version of the network used for simulating cognitive decline in Alzheimer's disease [4] , but with implementation of a different schizophrenia-type pathology.
An mGluR 5 -dependent delayed afterdepolarization current that can increase the spiking rate of pyramidal cells for several seconds was implemented as an alpha function in the model with a time constant similar to the observation in [34] . Based on insights from the relative number of pyramidal cells and interneurons [33, 35] , 40% of the interneurons synapsed with other GABA interneurons, but not with pyramidal cells.
A stimulus is initiated by injecting a current at t=2000 msec which starts the firing of the target pyramidal cells. Without further stimuli, this synchronized firing pattern goes on for a certain amount of time before it gets degraded by the background noise and the interference of the distractor neurons. This time span, called the working memory span, is usually in the range of 4-10 sec and corresponds to the time a certain pattern is held in working memory [36] .
To calculate this time span, we first divide the time axis in bins of 200 msec and count the number of neurons firing in that time window and determine the time points where this number exceeds M/2, where M is the number of neurons stimulated at t=2000 msec (M=10 for the network). The time difference between these two transition points is the memory span ( Fig   1B) .
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Physiological implementation Reference
Dopamine D1R Increases NMDA, decreases AMPA and increases GABA conductance [37] Dopamine D2R Presynaptic autoreceptor; modulates AMPAR on pyramidal cells [38] Dopamine D4R Affects AMPA-R functions [39] Serotonin 5-HT1A Affects Na-currents [40] , [41, 42] Serotonin 
Implementation of receptor pharmacology
This section deals specifically with the implementation of dopaminergic neurotransmission physiology. Other neuromodulatory processes (serotonergic. cholinergic, noradrenergic) are implemented using similar approaches. In general, we assume a linear 
The D 2 S receptor is a presynaptic autoreceptor in the cortex and regulates the activity level of the cortical D 1 and D 4 receptors [56] . This is taken into account by the cortical dopamine receptor competition model. Furthermore, D 2 R is located postsynaptically on pyramidal cells and modulates EPSP [38, 57] through an early AMPA mediated process and a late GABA mediated process. D2R activation modulates AMPA conductance according to
where D 2 A and D 2 C are actual D2 activation levels for treated subjects and healthy control levels, respectively and Param AMPA D2 is an adjustable parameter.
Dopamine D 4 R activation affects AMPA-R similarly but only on interneurons [39] . D4R activation increases the AMPA channel conductances such that
where D 4 A and D 4 C are actual D2 activation levels for treated subjects and healthy control levels, respectively and Param AMPA D4 is an adjustable parameter.
Calibrating the model
First the pathology of schizophrenia is implemented based on the observed changes in patients, a hypodopaminergic tone on the cortical D 1 R [32] , an NMDA hypofunction [58, 59] that is documented by a hypocortical-hyperstriatal imbalance in metabolic imaging [60] , a GABA deficit more specifically in the chandelier interneurons [61] but applied here to the interneurons in the network, and a more noisy background signal [62] . This leads to a cognitive deficit in schizophrenia patients which is dependent upon the clinical readout, but on average is 1.5 standard deviations lower than healthy controls [63] [64] [65] .
We will first explore the sensitivity of the network model outcome as a function of these four parameters to identify the possible biological drivers of pathology-driven network changes.
We then simulate the effect of 100 different virtual 'normal subjects' that have variable values around the optimal values. Based on the observation that schizophrenia patients perform at a level that is about 1.5 standard deviations lower than normals on a number of cognitive tests, we can then determine the minimal changes in the four parameters that corresponds to a network cognitive outcome as determined by this difference.
In a second step, the remaining free biological coupling factors such as Param AMPA D4 are further calibrated using clinical data on the N-back working memory test as reported in schizophrenia patients, healthy controls with anticholinergics or COMT inhibitors and stratified according to the COMT genotype. [66, 67] and healthy controls [68] with cholinergic changes and with COMT modulation [69] . For experiments where no COMT genotype data are available, we assume a COMT MV genotype.
The calibration of the network is performed using 'Design of Experiment' (DOE) statistical techniques, rather than OFAT (one Factor At a Time). OFAT techniques, besides being computationally intensive also are unable to detect interaction between parameters to be calibrated [70] . DOE techniques are computationally effective and provide a sound statistical approach to identify the driving parameters.
A good robust approach uses 2n simulations, where n is the number of free parameters, compared to 2 n for a full OFAT design [71] . Eq S15
where Neg ij = 0 if e ij = 'P' and Neg ij = 1 if e ij = 'M' Eq S16
The Pareto-effect, Par j (j=1..n), is simply the difference Average+ j -Average-j and indicates both the strength and the sign of the gradient towards the optimum.
The next iteration will use this information to adjust the range of the parameters, until the Pareto effects become so small that a more detailed surface response is initiated.
RESULTS
Implementation of schizophrenia pathology
We first studied the sensitivity of the network outcome on the different processes that are implicated in the schizophrenia pathology. Fig 2 shows the effect of changing the NMDA-R conductance in a range of 25%, the GABA conductance in a range of 10%; the D 1 R activation between 7 and 37% and the noise level between 36 and 84%. In terms of outcome variability (range of outcomes divided by average outcome) the greatest effect was observed for NMDA changes (0.63); followed by GABA changes (0.43), noise (0.26) and D1R activation level (0.16).
In general, the outcome decreases when introducing the pathology. For instance increasing the noise leads to a monotonic decrease of working memory span. However, for changes in the NMDA conductance, the maximum is around 0.92, suggesting that the first decrease leads to an improvement, probably due to the relatively bigger effect on the excitatoryinhibitory glutamate synapses that tend to decrease the inhibitory tone and lead to a disinhibition.
After a certain value is reached the decrease in excitatory-excitatory glutamate strength tend to reduce network activity. 
